Rare diseases
Investigational molecules
Locations
Back to Romania660 clinical trials in Bucharest, Romania across 19 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in RomaniaStudii.Clinice.ro(opens in a new tab)A study testing vipoglanstat for women with moderate to severe endometriosis-related pain
RomaniaA Study of GSK4524101 and Niraparib for Adults with Advanced Solid Tumors or Metastatic Breast Cancer with BRCA Gene Changes
RomaniaA study testing cagrilintide for weight loss in people with overweight or obesity and type 2 diabetes
RomaniaA study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation
RomaniaStudy of oral and injectable NNC0487-0111 (Amycretin) to find the best dose for blood sugar control in adults with type 2 diabetes taking metformin with or without SGLT2 inhibitor
RomaniaStudy of efavaleukin alfa safety and effectiveness in adults with moderate to severe ulcerative colitis
RomaniaStudy of Efavaleukin Alfa to Treat Adults with Moderate to Severe Ulcerative Colitis
RomaniaStudy of tozorakimab to reduce exacerbations in former smokers with chronic obstructive pulmonary disease (COPD)
RomaniaStudy of subcutaneous nivolumab with ipilimumab and chemotherapy in previously untreated patients with metastatic or recurrent non-small cell lung cancer
RomaniaComparing weekly insulin icodec and daily insulin glargine with insulin aspart in adults with type 1 diabetes: a 26-week study of blood sugar control
RomaniaLong-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial
RomaniaStudy of zolbetuximab, pembrolizumab and chemotherapy in adults with HER2-negative, Claudin 18.
RomaniaThe busiest research cities in the country
What the registry says about research in the country
Clinical trial activity in Bucuresti includes a strong focus on cardiovascular diseases, with studies targeting atherosclerotic risk and event prevention in high-risk patients.
These trials are mainly designed to evaluate new approaches that may lower the chance of heart attacks, strokes, and other serious vascular complications.
The nervous system diseases portfolio covers conditions affecting cognition, movement, and headache disorders, reflecting a broad interest in neurological care and symptom control.
Research here is focused on testing treatments that may improve daily functioning, reduce symptoms, and support long-term management in both adults and pediatric patients.
Trials in mental disorders are examining new options for people living with schizophrenia, especially those who do not respond well to standard antipsychotic treatment.
The overall aim is to better control symptoms and improve treatment effectiveness for patients with ongoing psychiatric needs.
In the area of respiratory tract diseases, studies are centered on moderate-to-severe uncontrolled asthma, with attention on therapies that may offer better symptom control.
These trials are exploring whether investigational therapies can help patients breathe more easily and reduce the burden of persistent asthma.
Research in nutritional and metabolic diseases includes studies on obesity and overweight, as well as related joint problems that often accompany excess body weight.
The goal is to assess therapies that may support weight management and improve associated health outcomes, including joint pain and mobility.
Oncology research in Bucuresti includes trials for limited-stage small cell lung cancer after chemoradiotherapy, with a focus on consolidation treatment strategies.
These studies are evaluating whether new immunotherapy combinations can help maintain remission and improve survival outcomes.
Some trials bring together neurology and psychiatry by studying agitation in Alzheimer’s disease, an important symptom that can affect patients and caregivers alike.
The research is intended to find better ways to manage distressing behavioral symptoms while supporting longer-term treatment use.
Another active area involves patients with ESKD undergoing dialysis, where studies are exploring inflammatory markers linked to cardiovascular risk.
These trials aim to better understand whether new therapies can help reduce inflammation and potentially improve overall health outcomes in this high-risk group.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
